Bicara Therapeutics Files 8-K on Shareholder Matters

Ticker: BCAX · Form: 8-K · Filed: Jun 12, 2025 · CIK: 2023658

Bicara Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyBicara Therapeutics Inc. (BCAX)
Form Type8-K
Filed DateJun 12, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: BCAX

TL;DR

Bicara Therapeutics (BCAX) filed an 8-K for shareholder votes - watch for governance changes.

AI Summary

Bicara Therapeutics Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders as of June 9, 2025. The filing details the company's corporate structure and operational information, including its principal executive offices in Boston, MA.

Why It Matters

This filing indicates that Bicara Therapeutics Inc. is engaging in corporate actions requiring shareholder approval, which could impact the company's strategic direction and governance.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding shareholder matters and does not appear to contain significant new financial or operational risks.

Key Players & Entities

  • Bicara Therapeutics Inc. (company) — Registrant
  • 0002023658-25-000082 (filing_id) — Accession Number
  • June 9, 2025 (date) — Date of earliest event reported
  • June 12, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of incorporation
  • Boston, MA (location) — Principal executive offices
  • 617-468-4219 (phone_number) — Registrant's telephone number

FAQ

What specific matters were submitted to a vote of Bicara Therapeutics Inc. security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the header information.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on June 9, 2025.

What is the principal executive office address for Bicara Therapeutics Inc.?

The principal executive offices are located at 116 Huntington Avenue, Suite 703, Boston, MA 02116.

What is the SEC file number for Bicara Therapeutics Inc.?

The SEC file number for Bicara Therapeutics Inc. is 001-42271.

In which state was Bicara Therapeutics Inc. incorporated?

Bicara Therapeutics Inc. was incorporated in Delaware.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Bicara Therapeutics Inc. (BCAX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.